title: Biocompatibility of hemoglobin solutions. I. Reactions of vascular endothelial cells to pure and impure hemoglobins.
abstract: Hemoglobin (Hb) solutions can cause vasoconstriction and activation of intravascular coagulation. Because the endothelium plays a major role in the regulation of vascular tone and hemostasis, a study was conducted of human umbilical vein endothelial cells (EC) incubated with various Hbs. Cell injury was evaluated by electron microscopy and the release of lactic dehydrogenase, H2O2, and procoagulant "tissue factor." Cell reaction was assessed by the measurement of 6-keto-prostaglandin F (PGF)1 alpha (metabolite of prostacyclin) and thromboxane B2 (metabolite of thromboxane A2). Incubation with unmodified bovine hemoglobin for 24 h caused no cell injury and a reaction characterized by 48.4 +/- 8.2% increase in 6-keto-PGF1 alpha production, accompanied by 40.2 +/- 9.4% reduction in thromboxane (Tx)B2 (compared with a control group of EC incubated with saline solution). Incubation with a nonpure Hb solution (Hb plus red blood cell membrane aminophospholipids; a-PLs) caused cell injury with significant release of tissue factor, plus a reaction characterized by 97.5 +/- 12.5% increase in TxB2 production accompanied by 25.3 +/- 3% reduction in 6-keto-PGF1 alpha. A second nonpure Hb [Hb plus bacterial environmental endotoxin (E)] caused cell injury, the release of tissue factor, and increased production of both prostaglandins, with greater release of TxB2 (197 +/- 17%) than of 6-keto-PGF1 alpha (112 +/- 8.3%). These data indicate that the endothelium reacts differently to pure and nonpure hemoglobins. The biocompatibility of Hb solutions, with regard to vasoconstriction and activation of intravascular coagulation, depends on the absence of stromal a-PLs and bacterial E.
authors.affiliation: Department of Surgery, Texas Tech University Health Sciences Center, Lubbock 79430.
authors.forename: M
authors.initials: M
authors.lastname: Feola
authors.forename: J
authors.initials: J
authors.lastname: Simoni
authors.forename: D
authors.initials: D
authors.lastname: Fishman
authors.forename: R
authors.initials: R
authors.lastname: Tran
authors.forename: P C
authors.initials: PC
authors.lastname: Canizaro
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000633:toxicity; D001777:Blood Coagulation; D001802:Blood Substitutes / Q000633:toxicity*; D002417:Cattle; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis; D006454:Hemoglobins / Q000008:administration & dosage / Q000633:toxicity*; D012996:Solutions; D013929:Thromboxane B2 / Q000096:biosynthesis
chemical_list: D001672:Biocompatible Materials; D001802:Blood Substitutes; D006454:Hemoglobins; D012996:Solutions; D013929:Thromboxane B2; D011464:Epoprostenol